首页 /药靶模型 /药靶细胞 /免疫治疗 /PDL1 Target Cell (Adherent)

PDL1 Target Cell (Adherent)

CBP74240

询 价
索取Protocol
产品描述
产品数据库
I. Background
The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T cells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. The PD-1 ligands are found on most cancers, and PD-1:PD-L1/2 interaction inhibits T cell activity and allows cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes.
 
II. Introduction
Expressed gene: PDL1
Stability: 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)
Freeze Medium: 90% FBS+10% DMSO
Culture Medium: F12k+10%FBS+400 μg/ml hygromycin
Mycoplasma Testing: Negative
Storage: Liquid nitrogen
Application(s): Functional(Report Gene) Assay
 
III. Representative Data

Figure 1. Blocking of PD1 induced PD1 SHP2 Reporter Cell (C17) Activity by PD1 Neutralizing Antibody with PDL1 Target cell (Adherent).



Figure 2.Blocking of PDL1 induced PD1 SHP2 Reporter Cell (C17) Activity by Atezolizumab with PDL1 Target Cell (Adherent).


药靶模型联系方式: 华东销售经理:18240630236 全国销售经理:18066071954
诊断标准品联系方式: 华东销售经理:15000320447 华北销售经理:18131625521 华南销售经理:13484295986 华中&西南销售经理:13871580511 全国销售经理:13484295986

扫二维码

立即提交